Get the Stockscreener App
2.61
2.35%
0.06
After Hours:
2.51
-0.10
-3.83%
Maxcyte Inc stock is traded at $2.61, with a volume of 472.31K.
It is up +2.35% in the last 24 hours and down -19.94% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$2.55
Open:
$2.53
24h Volume:
472.31K
Relative Volume:
0.75
Market Cap:
$275.67M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-7.6765
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
+11.54%
1M Performance:
-19.94%
6M Performance:
-31.13%
1Y Performance:
-33.76%
1-Day Range:
$2.525
$2.63
1-Week Range:
$2.29
$2.74
52-Week Range:
$2.21
$5.26
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.61 | 275.67M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
Vanguard Group Inc. Sells 345,587 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
Cooley Advises Cell Therapy Biz On London Market Exit - Law360
MaxCyte intends to delist from London's AIM to enhance liquidity - marketscreener.com
MaxCyte to Delist from AIM, Focus on Nasdaq - TipRanks
MaxCyte Announces Change in Voting Rights Structure - TipRanks
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges By Investing.com - Investing.com South Africa
MaxCyte stock plunges to 52-week low of $2.25 amid market challenges - Investing.com India
MaxCyte sets date for Q1 2025 financial results reveal By Investing.com - Investing.com South Africa
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - The Manila Times
MaxCyte sets date for Q1 2025 financial results reveal - Investing.com
MaxCyte to Announce Q1 2025 Financial Results - TipRanks
Insider Buyers Lose US$201k As MaxCyte Sheds UK£32m - simplywall.st
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) - Yahoo Finance
With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns - Yahoo Finance
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround - Yahoo Finance
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - MSN
MaxCyte Inc (MXCT) Volatility Hits 6.24% – Here Is What You Should Do - Stocksregister
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges - Investing.com Australia
MaxCyte Stock Hits 52-Week Low at $2.62 Amid Market Challenges By Investing.com - Investing.com South Africa
MaxCyte Expands Capital with New Stock Issuance - TipRanks
Charles Schwab Investment Management Inc. Decreases Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte stock plunges to 52-week low, touches $2.75 - Investing.com
MaxCyte CFO completes RSU vesting and tax-related sale By Investing.com - Investing.com Australia
MaxCyte CFO completes RSU vesting and tax-related sale - Investing.com India
MaxCyte Announces CFO’s RSU Vesting and Share Sale - TipRanks
MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks
MaxCyte Announces Change in Major Shareholder Holdings - TipRanks
Bank of New York Mellon Corp Reduces Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte executives receive equity incentives By Investing.com - Investing.com South Africa
MaxCyte executives receive equity incentives - Investing.com India
MaxCyte Awards Stock Options and Units to Executives - TipRanks
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock By Investing.com - Investing.com Australia
MaxCyte chief commercial officer Ali Soleymannezhad sells $3,850 in stock - Investing.com India
Maxcyte general counsel David Sandoval sells $1,122 in stock - Investing.com
Maxcyte CFO Douglas Swirsky sells $22,061 in common stock - Investing.com
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):